1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Public Health
  4. Volume 45, 2024
  5. Article

Annual Review of Public Health

Volume 45, 2024

The Economics of Treatment for Depression

Abstract

The global prevalence of depression has risen over the past three decades across all socioeconomic groups and geographic regions, with a particularly rapid increase in prevalence among adolescents (aged 12–17 years) in the United States. Depression imposes large health, economic, and societal costs, including reduced life span and quality of life, medical costs, and reduced educational attainment and workplace productivity. A wide range of treatment modalities for depression are available, but socioeconomic disparities in treatment access are driven by treatment costs, lack of culturally tailored options, stigma, and provider shortages, among other barriers. This review highlights the need for comparative research to better understand treatments’ relative efficacy, cost-effectiveness, scalability, and potential heterogeneity in efficacy across socioeconomic groups and country and cultural contexts. To address the growing burden of depression, mental health policy could consider reducing restrictions on the supply of providers, implementing digital interventions, reducing stigma, and promoting healthy lifestyles.

Keyword(s): depression, depression treatment, economic consequences of depression, mental health services, population health, public health policy
Loading

Article metrics loading...

/content/journals/10.1146/annurev-publhealth-061022-040533
2024-05-20
2024-05-21
Loading full text...

Full text loading...

/deliver/fulltext/publhealth/45/1/annurev-publhealth-061022-040533.html?itemId=/content/journals/10.1146/annurev-publhealth-061022-040533&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Adiukwu F, de Filippis R, Orsolini L, Gashi Bytyçi D, Shoib S, et al. 2022.. Scaling up global mental health services during the COVID-19 pandemic and beyond. . Psychiatr. Serv. 73:(2):231–34
     [Crossref] [Google Scholar]
  2. 2.
    Alabaku O, Yang A, Tharmarajah S, Suda K, Vigod S, Tadrous M. 2023.. Global trends in antidepressant, atypical antipsychotic, and benzodiazepine use: a cross-sectional analysis of 64 countries. . PLOS ONE 18:(4):e0284389
     [Crossref] [Google Scholar]
  3. 3.
    Alegría M, Alvarez K, Ishikawa RZ, DiMarzio K, McPeck S. 2016.. Removing obstacles to eliminating racial and ethnic disparities in behavioral health care. . Health Aff. 35:(6):991–99
     [Crossref] [Google Scholar]
  4. 4.
    Alegría M, Chatterji P, Wells K, Cao Z, Chen C-N, et al. 2008.. Disparity in depression treatment among racial and ethnic minority populations in the United States. . Psychiatr. Serv. 59:(11):1264–72
     [Crossref] [Google Scholar]
  5. 5.
    APA (Am. Psychiatr. Assoc.). 2021.. New nationwide poll shows an increased popularity for telehealth services. News Release, May 27. https://www.psychiatry.org/news-room/news-releases/new-nationwide-poll-shows-an-increased-popularity
  6. 6.
    Amiri S. 2022.. Unemployment associated with major depression disorder and depressive symptoms: a systematic review and meta-analysis. . Int. J. Occup. Saf. Ergon. 28:(4):2080–92
     [Crossref] [Google Scholar]
  7. 7.
    Anderson PL, McLellan RD, Overton JP, Wolfram GL. 1997.. Price elasticity of demand. . In The universal tuition tax credit: a proposal to advance parental choice in education. Rep. , Mackinac Cent. Public Policy, Midland, MI:. https://www.mackinac.org/1247
    [Google Scholar]
  8. 8.
    Andersson G, Titov N. 2014.. Advantages and limitations of Internet-based interventions for common mental disorders. . World Psychiatry 13:(1):4–11
     [Crossref] [Google Scholar]
  9. 9.
    Andrews G, Basu A, Cuijpers P, Craske MG, McEvoy P, et al. 2018.. Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: an updated meta-analysis. . J. Anxiety Disord. 55::70–78
     [Crossref] [Google Scholar]
  10. 10.
    Bachmann CJ, Aagaard L, Burcu M, Glaeske G, Kalverdijk LJ, et al. 2016.. Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005–2012. . Eur. Neuropsychopharmacol. 26:(3):411–19
     [Crossref] [Google Scholar]
  11. 11.
    Baicker K, Chandra A, Skinner JS, Wennberg JE. 2004.. Who you are and where you live: how race and geography affect the treatment of Medicare beneficiaries. . Health Aff. 23:(Suppl. 2):VAR33–44
     [Crossref] [Google Scholar]
  12. 12.
    Barnato AE, Lucas FL, Staiger D, Wennberg DE, Chandra A. 2005.. Hospital-level racial disparities in acute myocardial infarction treatment and outcomes. . Med. Care 43:(4):308–19
     [Crossref] [Google Scholar]
  13. 13.
    Barth M, Kriston L, Klostermann S, Barbui C, Cipriani A, Linde K. 2016.. Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials. . Br. J. Psychiatry 208:(2):114–19
     [Crossref] [Google Scholar]
  14. 14.
    Berndt ER, Bir A, Busch SH, Frank RG, Normand S-LT. 2002.. The medical treatment of depression, 1991–1996: productive inefficiency, expected outcome variations, and price indexes. . J. Health Econ. 21:(3):373–96
     [Crossref] [Google Scholar]
  15. 15.
    Berndt ER, Koran LM, Finkelstein SN, Gelenberg AJ, Kornstein SG, et al. 2000.. Lost human capital from early-onset chronic depression. . Am. J. Psychiatry 157:(6):940–47
     [Crossref] [Google Scholar]
  16. 16.
    Birmaher B, Brent D, AACAP Work. Group Qual. Issues. 2007.. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. . J. Am. Acad. Child Adolesc. Psychiatry 46:(11):1503–26
     [Crossref] [Google Scholar]
  17. 17.
    Bockting CL, Hollon SD, Jarrett RB, Kuyken W, Dobson K. 2015.. A lifetime approach to major depressive disorder: the contributions of psychological interventions in preventing relapse and recurrence. . Clin. Psychol. Rev. 41::16–26
     [Crossref] [Google Scholar]
  18. 18.
    Bolton JM, Dahl M, Sareen J, Enns MW, Leslie WD, et al. 2012.. A population-based study of the use of selective serotonin reuptake inhibitors before and after introduction of generic equivalents. . Can. J. Psychiatry 57:(4):223–29
     [Crossref] [Google Scholar]
  19. 19.
    Bottomley JM, LeReun C, Diamantopoulos A, Mitchell S, Gaynes BN. 2020.. Vagus nerve stimulation (VNS) therapy in patients with treatment resistant depression: a systematic review and meta-analysis. . Compr. Psychiatry 98::152156
     [Crossref] [Google Scholar]
  20. 20.
    Brauer R, Alfageh B, Blais JE, Chan EW, Chui CSL, et al. 2021.. Psychotropic medicine consumption in 65 countries and regions, 2008–19: a longitudinal study. . Lancet Psychiatry 8:(12):1071–82
     [Crossref] [Google Scholar]
  21. 21.
    Byrow Y, Pajak R, Specker P, Nickerson A. 2020.. Perceptions of mental health and perceived barriers to mental health help-seeking amongst refugees: a systematic review. . Clin. Psychol. Rev. 75::101812
     [Crossref] [Google Scholar]
  22. 22.
    Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, et al. 2021.. Trial of psilocybin versus escitalopram for depression. . N. Engl. J. Med. 384:(15):1402–11
     [Crossref] [Google Scholar]
  23. 23.
    Carlo AD, Hosseini Ghomi R, Renn BN, Areán PA. 2019.. By the numbers: ratings and utilization of behavioral health mobile applications. . NPJ Digit. Med. 2:(1):54
     [Crossref] [Google Scholar]
  24. 24.
    Ceolin G, Breda V, Koning E, Meyyappan AC, Gomes FA, et al. 2022.. A possible antidepressive effect of dietary interventions: emergent findings and research challenges. . Curr. Treat. Options Psychiatry 9:(3):151–62
     [Crossref] [Google Scholar]
  25. 25.
    Chen S, Ford TJ, Jones PB, Cardinal RN. 2022.. Prevalence, progress, and subgroup disparities in pharmacological antidepressant treatment of those who screen positive for depressive symptoms: a repetitive cross-sectional study in 19 European countries. . Lancet Reg. Health Eur. 17::100368
     [Crossref] [Google Scholar]
  26. 26.
    Cheng N, Banerjee T, Qian J, Hansen RA. 2017.. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011. . J. Am. Pharm. Assoc. 57:(3):341–48
     [Crossref] [Google Scholar]
  27. 27.
    Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, et al. 2018.. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. . Lancet 391:(10128):1357–66
     [Crossref] [Google Scholar]
  28. 28.
    Conley AA, Norwood AEQ, Hatvany TC, Griffith JD, Barber KE. 2021.. Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: a meta-analysis. . Psychopharmacology 238:(7):1737–52
     [Crossref] [Google Scholar]
  29. 29.
    Copeland WE, Wolke D, Shanahan L, Costello EJ. 2015.. Adult functional outcomes of common childhood psychiatric problems: a prospective, longitudinal study. . JAMA Psychiatry 72:(9):892–99
     [Crossref] [Google Scholar]
  30. 30.
    Cronin CJ, Forsstrom MP, Papageorge NW. 2020.. What good are treatment effects without treatment? Mental health and the reluctance to use talk therapy. NBER Work. Pap. 27711. https://www.nber.org/system/files/working_papers/w27711/w27711.pdf
  31. 31.
    Cuellar AE. 2022.. Parity and provider networks. . Psychiatr. Serv. 73:(9):961
     [Crossref] [Google Scholar]
  32. 32.
    Cuijpers P, Berking M, Andersson G, Quigley L, Kleiboer A, Dobson KS. 2013.. A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. . Can. J. Psychiatry 58:(7):376–85
     [Crossref] [Google Scholar]
  33. 33.
    Cuijpers P, Karyotaki E, de Wit L, Ebert DD. 2020.. The effects of fifteen evidence-supported therapies for adult depression: a meta-analytic review. . Psychother. Res. 30:(3):279–93
     [Crossref] [Google Scholar]
  34. 34.
    Cuijpers P, Oud M, Karyotaki E, Noma H, Quero S, et al. 2021.. Psychologic treatment of depression compared with pharmacotherapy and combined treatment in primary care: a network meta-analysis. . Ann. Fam. Med. 19:(3):262–70
     [Crossref] [Google Scholar]
  35. 35.
    Cuijpers P, Smit F, Bohlmeijer E, Hollon SD, Andersson G. 2010.. Efficacy of cognitive-behavioural therapy and other psychological treatments for adult depression: meta-analytic study of publication bias. . Br. J. Psychiatry 196:(3):173–78
     [Crossref] [Google Scholar]
  36. 36.
    Curran J. 2008.. The Yellow Emperor's Classic of Internal Medicine. . BMJ 336:(7647):777
     [Crossref] [Google Scholar]
  37. 37.
    Dasgupta A, Lawson KA. 2013.. Utilization of and expenditures for selective serotonin reuptake inhibitors (SSRIs) and factors associated with change in price per-prescription of brand SSRIs in the Texas Medicaid programme (1991–2009). . J. Pharm. Health Serv. Res. 4:(2):105–13
     [Crossref] [Google Scholar]
  38. 38.
    Deighton J, Lereya ST, Casey P, Patalay P, Humphrey N, Wolpert M. 2019.. Prevalence of mental health problems in schools: poverty and other risk factors among 28 000 adolescents in England. . Br. J. Psychiatry 215:(3):565–67
     [Crossref] [Google Scholar]
  39. 39.
    Delaloye S, Holtzheimer PE. 2014.. Deep brain stimulation in the treatment of depression. . Dialogues Clin. Neurosci. 16:(1):83–91
     [Crossref] [Google Scholar]
  40. 40.
    Delgadillo J, Asaria M, Ali S, Gilbody S. 2016.. On poverty, politics and psychology: the socioeconomic gradient of mental healthcare utilisation and outcomes. . Br. J. Psychiatry 209:(5):429–30
     [Crossref] [Google Scholar]
  41. 41.
    Deshauer D, Moher D, Fergusson D, Moher E, Sampson M, Grimshaw J. 2008.. Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. . CMAJ 178:(10):1293–301
     [Crossref] [Google Scholar]
  42. 42.
    Desimone J, Markowitz S. 2003.. The effect of price on counselling sessions attended by depression patients. . Appl. Econ. Lett. 10:(14):899–903
     [Crossref] [Google Scholar]
  43. 43.
    Dibato J, Montvida O, Polonsky WH, Chin KL, Paul SK. 2022.. Young adult depression, antidepressant prescriptions, and therapy intensification in people with incident depression in the United States. . Prim. Care Companion CNS Disord. 24:(5):42658
     [Crossref] [Google Scholar]
  44. 44.
    Domino ME, Dow WH, Coto-Yglesias F. 2014.. Educational gradients in psychotropic medication use among older adults in Costa Rica and the United States. . Psychiatr. Serv. 65:(10):1218–25
     [Crossref] [Google Scholar]
  45. 45.
    Domino ME, Salkever DS. 2003.. Price elasticity and pharmaceutical selection: the influence of managed care. . Health Econ. 12:(7):565–86
     [Crossref] [Google Scholar]
  46. 46.
    Doshi JA, Cen L, Polsky D. 2008.. Depression and retirement in late middle-aged U.S. workers. . Health Serv. Res. 43:(2):693–713
     [Crossref] [Google Scholar]
  47. 47.
    Drevets WC, Wittenberg GM, Bullmore ET, Manji HK. 2022.. Immune targets for therapeutic development in depression: towards precision medicine. . Nat. Rev. Drug Discov. 21:(3):224–44
     [Crossref] [Google Scholar]
  48. 48.
    Ekers D, Richards D, Gilbody S. 2008.. A meta-analysis of randomized trials of behavioural treatment of depression. . Psychol. Med. 38:(5):611–23
     [Crossref] [Google Scholar]
  49. 49.
    Ellis RP, Martins B, Zhu W. 2017.. Health care demand elasticities by type of service. . J. Health Econ. 55::232–43
     [Crossref] [Google Scholar]
  50. 50.
    EPIC Healing Eugene. 2023.. EPIC Healing Eugene. . Eugene Psychedelic Integrative Center. https://www.epichealingeugene.com/faq
    [Google Scholar]
  51. 51.
    Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. 2020.. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. . JAMA Netw. Open 3:(9):e2019686
     [Crossref] [Google Scholar]
  52. 52.
    Ettner SL, Frank RG, Kessler RC. 1997.. The impact of psychiatric disorders on labor market outcomes. . ILR Rev. 51:(1):64–81
     [Crossref] [Google Scholar]
  53. 53.
    Evans-Lacko S, Knapp M. 2016.. Global patterns of workplace productivity for people with depression: absenteeism and presenteeism costs across eight diverse countries. . Soc. Psychiatry Psychiatr. Epidemiol. 51:(11):1525–37
     [Crossref] [Google Scholar]
  54. 54.
    Evensen K, Jørgensen MB, Sabers A, Martiny K. 2022.. Transcutaneous vagal nerve stimulation in treatment-resistant depression: a feasibility study. . Neuromodulation 25:(3):443–49
     [Crossref] [Google Scholar]
  55. 55.
    Eyre H, Baune BT. 2012.. Neuroimmunological effects of physical exercise in depression. . Brain Behav. Immunity 26:(2):251–66
     [Crossref] [Google Scholar]
  56. 56.
    Feldman RP, Goodrich JT. 2001.. Psychosurgery: a historical overview. . Neurosurgery 48:(3):647–57
     [Crossref] [Google Scholar]
  57. 57.
    Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, et al. 2013.. Burden of depressive disorders by country, sex, age, and year: findings from the Global Burden of Disease study 2010. . PLOS Med. 10:(11):e1001547
     [Crossref] [Google Scholar]
  58. 58.
    Firth J, Marx W, Dash S, Carney R, Teasdale SB, et al. 2019.. The effects of dietary improvement on symptoms of depression and anxiety: a meta-analysis of randomized controlled trials. . Psychosom. Med. 81:(3):265–80
     [Crossref] [Google Scholar]
  59. 59.
    Firth J, Torous J, Nicholas J, Carney R, Pratap A, et al. 2017.. The efficacy of smartphone-based mental health interventions for depressive symptoms: a meta-analysis of randomized controlled trials. . World Psychiatry 16:(3):287–98
     [Crossref] [Google Scholar]
  60. 60.
    Fletcher J. 2013.. Adolescent depression and adult labor market outcomes. . South. Econ. J. 80:(1):26–49
     [Crossref] [Google Scholar]
  61. 61.
    Fletcher JM. 2010.. Adolescent depression and educational attainment: results using sibling fixed effects. . Health Econ. 19:(7):855–71
     [Crossref] [Google Scholar]
  62. 62.
    Fortney JC, Harman JS, Xu S, Dong F. 2010.. The association between rural residence and the use, type, and quality of depression care. . J. Rural Health 26:(3):205–13
     [Crossref] [Google Scholar]
  63. 63.
    Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, et al. 2010.. Antidepressant drug effects and depression severity: a patient-level meta-analysis. . JAMA 303:(1):47–53
     [Crossref] [Google Scholar]
  64. 64.
    Frank RG, McGuire TG. 2000.. Economics and mental health. . In Handbook of Health Economics, ed. AJ Culyer, JP Newhouse , pp. 893–954. Amsterdam:: Elsevier
     [Google Scholar]
  65. 65.
    Frank RG, Zeckhauser RJ. 2007.. Custom-made versus ready-to-wear treatments: behavioral propensities in physicians’ choices. . J. Health Econ. 26:(6):1101–27
     [Crossref] [Google Scholar]
  66. 66.
    Franzen PL, Buysse DJ. 2008.. Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. . Dialogues Clin. Neurosci. 10:(4):473–81
     [Crossref] [Google Scholar]
  67. 67.
    Freeman D, Sheaves B, Waite F, Harvey AG, Harrison PJ. 2020.. Sleep disturbance and psychiatric disorders. . Lancet Psychiatry 7:(7):628–37
     [Crossref] [Google Scholar]
  68. 68.
    Fu Z, Burger H, Arjadi R, Bockting CLH. 2020.. Effectiveness of digital psychological interventions for mental health problems in low-income and middle-income countries: a systematic review and meta-analysis. . Lancet Psychiatry 7:(10):851–64
     [Crossref] [Google Scholar]
  69. 69.
    Gál É, Ştefan S, Cristea IA. 2021.. The efficacy of mindfulness meditation apps in enhancing users’ well-being and mental health related outcomes: a meta-analysis of randomized controlled trials. . J. Affect. Disord. 279::131–42
     [Crossref] [Google Scholar]
  70. 70.
    Gardner P. 2003.. Distorted packaging: marketing depression as illness, drugs as cure. . J. Med. Humanit. 24:(1):105–30
     [Crossref] [Google Scholar]
  71. 71.
    Gee B, Orchard F, Clarke E, Joy A, Clarke T, Reynolds S. 2019.. The effect of non-pharmacological sleep interventions on depression symptoms: a meta-analysis of randomised controlled trials. . Sleep Med. Rev. 43::118–28
     [Crossref] [Google Scholar]
  72. 72.
    Germinario G, Amin V, Flores CA, Flores-Lagunes A. 2022.. What can we learn about the effect of mental health on labor market outcomes under weak assumptions? Evidence from the NLSY79. . Labour Econ. 79::102258
     [Crossref] [Google Scholar]
  73. 73.
    Godman B, Persson M, Miranda J, Skiöld P, Wettermark B, et al. 2013.. Changes in the utilization of venlafaxine after the introduction of generics in Sweden. . Appl. Health Econ. Health Policy 11:(4):383–93
     [Crossref] [Google Scholar]
  74. 74.
    Golden SH, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, et al. 2008.. Examining a bidirectional association between depressive symptoms and diabetes. . JAMA 299:(23):2751–59
     [Crossref] [Google Scholar]
  75. 75.
    Goodman LA, Pugach M, Skolnik A, Smith L. 2013.. Poverty and mental health practice: within and beyond the 50-minute hour. . J. Clin. Psychol. 69:(2):182–90
     [Crossref] [Google Scholar]
  76. 76.
    Goodwin RD, Dierker LC, Wu M, Galea S, Hoven CW, Weinberger AH. 2022.. Trends in U.S. depression prevalence from 2015 to 2020: the widening treatment gap. . Am. J. Prev. Med. 63:(5):726–33
     [Crossref] [Google Scholar]
  77. 77.
    Goyal M, Singh S, Sibinga EMS, Gould NF, Rowland-Seymour A, et al. 2014.. Meditation programs for psychological stress and well-being: a systematic review and meta-analysis. . JAMA Intern. Med. 174:(3):357–68
     [Crossref] [Google Scholar]
  78. 78.
    Gray AL, Santa-Ana-Tellez Y, Wirtz VJ. 2016.. Impact of the introduction of mandatory generic substitution in South Africa: private sector sales of generic and originator medicines for chronic diseases. . Trop. Med. Int. Health 21:(12):1504–12
     [Crossref] [Google Scholar]
  79. 79.
    Green JG, McLaughlin KA, Fillbrunn M, Fukuda M, Jackson JS, et al. 2020.. Barriers to mental health service use and predictors of treatment drop out: racial/ethnic variation in a population-based study. . Adm. Policy Ment. Health 47:(4):606–16
     [Crossref] [Google Scholar]
  80. 80.
    Greenberg PE, Fournier A-A, Sisitsky T, Simes M, Berman R, et al. 2021.. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). . Pharmacoeconomics 39:(6):653–65
     [Crossref] [Google Scholar]
  81. 81.
    Greenstone G. 2010.. The history of bloodletting. . B. C. Med. J. 52:(1):12–14
     [Google Scholar]
  82. 82.
    Grenard JL, Munjas BA, Adams JL, Suttorp M, Maglione M, et al. 2011.. Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis. . J. Gen. Intern. Med. 26:(10):1175–82
     [Crossref] [Google Scholar]
  83. 83.
    Gualano MR, Bert F, Mannocci A, La Torre G, Zeppegno P, Siliquini R. 2014.. Consumption of antidepressants in Italy: recent trends and their significance for public health. . Psychiatr. Serv. 65:(10):1226–31
     [Crossref] [Google Scholar]
  84. 84.
    Hallmann-Mikołajczak A. 2004.. [ Ebers Papyrus. The book of medical knowledge of the 16th century B.C. Egyptians. ]. Arch. Hist. Filoz Med. 67:(1):5–14
     [Google Scholar]
  85. 85.
    Halonen JI, Koskinen A, Kouvonen A, Varje P, Pirkola S, Väänänen A. 2018.. Distinctive use of newer and older antidepressants in major geographical areas: a nationally representative register-based study. . J. Affect. Disord. 229::358–63
     [Crossref] [Google Scholar]
  86. 86.
    Hansen T, Slagsvold B, Veenstra M. 2017.. Educational inequalities in late-life depression across Europe: results from the generations and gender survey. . Eur. J. Ageing 14:(4):407–18
     [Crossref] [Google Scholar]
  87. 87.
    Harvey AG, Murray G, Chandler RA, Soehner A. 2011.. Sleep disturbance as transdiagnostic: consideration of neurobiological mechanisms. . Clin. Psychol. Rev. 31:(2):225–35
     [Crossref] [Google Scholar]
  88. 88.
    Healy D. 2015.. Serotonin and depression. . BMJ 350::h1771
     [Crossref] [Google Scholar]
  89. 89.
    Hegel MT, Oxman TE, Hull JG, Swain K, Swick H. 2006.. Watchful waiting for minor depression in primary care: remission rates and predictors of improvement. . Gen. Hosp. Psychiatry 28:(3):205–12
     [Crossref] [Google Scholar]
  90. 90.
    Heissel A, Heinen D, Brokmeier LL, Skarabis N, Kangas M, et al. 2023.. Exercise as medicine for depressive symptoms? A systematic review and meta-analysis with meta-regression. . Br. J. Sports Med. 57::1049–57
     [Crossref] [Google Scholar]
  91. 91.
    Hejzlar M, Novak T, Bares M. 2021.. Neurostimulation methods in the treatment of depression: a comparison of rTMS, tDCS, and venlafaxine using a pooled analysis of two studies. . Neuropsychiatr. Dis. Treat. 17::1713–22
     [Crossref] [Google Scholar]
  92. 92.
    Heller AC, Amar AP, Liu CY, Apuzzo MLJ. 2008.. Surgery of the mind and mood: a mosaic of issues in time and evolution. . Neurosurgery 62:(6 Suppl. 3):921–40
     [Crossref] [Google Scholar]
  93. 93.
    Hellmann SS, Møller SP, Ersbøll AK, Santini ZI, Nielsen MBD, et al. 2023.. Labor force participation during COVID-19 and risk of depression: a Danish register study. . Eur. J. Public Health 33:(1):80–86
     [Crossref] [Google Scholar]
  94. 94.
    Hockenberry JM, Joski P, Yarbrough C, Druss BG. 2019.. Trends in treatment and spending for patients receiving outpatient treatment of depression in the United States, 1998–2015. . JAMA Psychiatry 76:(8):810–17
     [Crossref] [Google Scholar]
  95. 95.
    Hofmann SG, Asnaani A, Vonk IJJ, Sawyer AT, Fang A. 2012.. The efficacy of cognitive behavioral therapy: a review of meta-analyses. . Cogn. Ther. Res. 36:(5):427–40
     [Crossref] [Google Scholar]
  96. 96.
    Hofmann SG, Sawyer AT, Witt AA, Oh D. 2010.. The effect of mindfulness-based therapy on anxiety and depression: a meta-analytic review. . J. Consult. Clin. Psychol. 78::169–83
     [Crossref] [Google Scholar]
  97. 97.
    Hossain MM, Nesa F, Das J, Aggad R, Tasnim S, et al. 2022.. Global burden of mental health problems among children and adolescents during COVID-19 pandemic: an umbrella review. . Psychiatry Res. 317::114814
     [Crossref] [Google Scholar]
  98. 98.
    Hu MX, Turner D, Generaal E, Bos D, Ikram MK, et al. 2020.. Exercise interventions for the prevention of depression: a systematic review of meta-analyses. . BMC Public Health 20:(1):1255
     [Crossref] [Google Scholar]
  99. 99.
    Huberty J, Puzia ME, Green J, Vlisides-Henry RD, Larkey L, et al. 2021.. A mindfulness meditation mobile app improves depression and anxiety in adults with sleep disturbance: analysis from a randomized controlled trial. . Gen. Hosp. Psychiatry 73::30–37
     [Crossref] [Google Scholar]
  100. 100.
    Huijbregts KM, Hoogendoorn AW, Slottje P, van Balkom AJLM, Batelaan NM. 2017.. Long-term and short-term antidepressant use in general practice: data from a large cohort in the Netherlands. . Psychother. Psychosomat. 86:(6):362–69
     [Crossref] [Google Scholar]
  101. 101.
    Huskamp HA, Donohue JM, Koss C, Berndt ER, Frank RG. 2008.. Generic entry, reformulations and promotion of SSRIs in the US. . Pharmacoeconomics 26:(7):603–16
     [Crossref] [Google Scholar]
  102. 102.
    Hyman SE. 2012.. Revolution stalled. . Sci. Transl. Med. 4:(155):155cm11
     [Crossref] [Google Scholar]
  103. 103.
    Iglesias-González M, Aznar-Lou I, Gil-Girbau M, Moreno-Peral P, Peñarrubia-María MT, et al. 2017.. Comparing watchful waiting with antidepressants for the management of subclinical depression symptoms to mild-moderate depression in primary care: a systematic review. . Fam. Pract. 34:(6):639–48
     [Crossref] [Google Scholar]
  104. 104.
    Iglesias-González M, Aznar-Lou I, Peñarrubia-María MT, Gil-Girbau M, Fernández-Vergel R, et al. 2018.. Effectiveness of watchful waiting versus antidepressants for patients diagnosed of mild to moderate depression in primary care: a 12-month pragmatic clinical trial (INFAP study). . Eur. Psychiatry 53::66–73
     [Crossref] [Google Scholar]
  105. 105.
    Ioannidis JPA. 2008.. Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?. Philos. Ethics Humanit. Med. 3:(1):14
     [Crossref] [Google Scholar]
  106. 106.
    Iranpour S, Sabour S, Koohi F, Saadati HM. 2022.. The trend and pattern of depression prevalence in the U.S.: data from National Health and Nutrition Examination Survey (NHANES) 2005 to 2016. . J. Affect. Disord. 298::508–15
     [Crossref] [Google Scholar]
  107. 107.
    Jackson JL, DeZee K, Berbano E. 2004.. Can treating depression improve disease outcomes?. Ann. Intern. Med. 140:(12):1054–56
     [Crossref] [Google Scholar]
  108. 108.
    Jakobsen JC, Katakam KK, Schou A, Hellmuth SG, Stallknecht SE, et al. 2017.. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. . BMC Psychiatry 17:(1):58
     [Crossref] [Google Scholar]
  109. 109.
    Jansson Å. 2021.. Introduction: disordered mood as historical problem. . In From Melancholia to Depression: Disordered Mood in Nineteenth-Century Psychiatry, ed. Å Jansson , pp. 1–33. Cham, Switz.:: Springer
     [Google Scholar]
  110. 110.
    Johnson J, Hall LH, Berzins K, Baker J, Melling K, Thompson C. 2018.. Mental healthcare staff well-being and burnout: a narrative review of trends, causes, implications, and recommendations for future interventions. . Int. J. Ment. Health Nurs. 27:(1):20–32
     [Crossref] [Google Scholar]
  111. 111.
    Josephine K, Josefine L, Philipp D, David E, Harald B. 2017.. Internet- and mobile-based depression interventions for people with diagnosed depression: a systematic review and meta-analysis. . J. Affect. Disord. 223::28–40
     [Crossref] [Google Scholar]
  112. 112.
    Kamel LY, Xiong W, Gott BM, Kumar A, Conway CR. 2022.. Vagus nerve stimulation: an update on a novel treatment for treatment-resistant depression. . J. Neurol. Sci. 434::120171
     [Crossref] [Google Scholar]
  113. 113.
    Kandola A, Ashdown-Franks G, Hendrikse J, Sabiston CM, Stubbs B. 2019.. Physical activity and depression: towards understanding the antidepressant mechanisms of physical activity. . Neurosci. Biobehav. Rev. 107::525–39
     [Crossref] [Google Scholar]
  114. 114.
    Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. 2015.. Trends in prescription drug use among adults in the United States from 1999–2012. . JAMA 314:(17):1818–30
     [Crossref] [Google Scholar]
  115. 115.
    Keeler EB, Manning WG, Wells KB. 1988.. The demand for episodes of mental health services. . J. Health Econ. 7:(4):369–92
     [Crossref] [Google Scholar]
  116. 116.
    Kellner CH, Greenberg RM, Murrough JW, Bryson EO, Briggs MC, Pasculli RM. 2012.. ECT in treatment-resistant depression. . Am. J. Psychiatry 169:(12):1238–44
     [Crossref] [Google Scholar]
  117. 117.
    Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, et al. 2009.. Randomised controlled trial to determine the clinical and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. . Health Technol. Assess. 13:(22):1–159
     [Crossref] [Google Scholar]
  118. 118.
    Kessler RC, Barber C, Birnbaum HG, Frank RG, Greenberg PE, et al. 1999.. Depression in the workplace: effects on short-term disability. . Health Aff. 18:(5):163–71
     [Crossref] [Google Scholar]
  119. 119.
    Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ. 1996.. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. . Am. J. Orthopsychiatry 66:(1):17–31
     [Crossref] [Google Scholar]
  120. 120.
    Kessler RC, Sampson NA, Berglund P, Gruber MJ, Al-Hamzawi A, et al. 2015.. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. . Epidemiol. Psychiatr. Sci. 24:(3):210–26
     [Crossref] [Google Scholar]
  121. 121.
    Kim J, Schwartz TL. 2020.. Chapter 7 - Psychiatric comorbidity in major depressive disorder. . In Major Depressive Disorder, ed. RS McIntyre , pp. 91–102. Philadelphia, PA:: Elsevier
     [Google Scholar]
  122. 122.
    Kimbro LB, Mangione CM, Steers WN, Duru OK, McEwen L, et al. 2014.. Depression and all-cause mortality in persons with diabetes mellitus: Are older adults at higher risk? Results from the Translating Research Into Action for Diabetes Study. . J. Am. Geriatr. Soc. 62:(6):1017–22
     [Crossref] [Google Scholar]
  123. 123.
    Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. 2008.. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. . PLOS Med. 5:(2):e45
     [Crossref] [Google Scholar]
  124. 124.
    Klijs B, Kibele EUB, Ellwardt L, Zuidersma M, Stolk RP, et al. 2016.. Neighborhood income and major depressive disorder in a large Dutch population: results from the LifeLines Cohort study. . BMC Public Health 16:(1):773
     [Crossref] [Google Scholar]
  125. 125.
    Kniesner TJ, Powers RH, Croghan TW. 2005.. Provider type and depression treatment adequacy. . Health Policy 72:(3):321–32
     [Crossref] [Google Scholar]
  126. 126.
    Kopra EI, Ferris JA, Winstock AR, Kuypers KP, Young AH, Rucker JJ. 2023.. Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: findings from the Global Drug Survey 2020. . J. Psychopharmacol. 37::733–48
     [Crossref] [Google Scholar]
  127. 127.
    Krendl AC, Pescosolido BA. 2020.. Countries and cultural differences in the stigma of mental illness: the east-west divide. . J. Cross-Cult. Psychol. 51:(2):149–67
     [Crossref] [Google Scholar]
  128. 128.
    Kuhfuß M, Maldei T, Hetmanek A, Baumann N. 2021.. Somatic experiencing - effectiveness and key factors of a body-oriented trauma therapy: a scoping literature review. . Eur. J. Psychotraumatol. 12:(1):1929023
     [Crossref] [Google Scholar]
  129. 129.
    Kuyken W, Warren FC, Taylor RS, Whalley B, Crane C, et al. 2016.. Efficacy of mindfulness-based cognitive therapy in prevention of depressive relapse: an individual patient data meta-analysis from randomized trials. . JAMA Psychiatry 73:(6):565–74
     [Crossref] [Google Scholar]
  130. 130.
    Kvam S, Kleppe CL, Nordhus IH, Hovland A. 2016.. Exercise as a treatment for depression: a meta-analysis. . J. Affect. Disord. 202::67–86
     [Crossref] [Google Scholar]
  131. 131.
    Lacasse JR, Leo J. 2005.. Serotonin and depression: a disconnect between the advertisements and the scientific literature. . PLOS Med. 2:(12):e392
     [Crossref] [Google Scholar]
  132. 132.
    Lapin IP, Oxenkrug GF. 1969.. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. . Lancet 293:(7586):132–36
     [Crossref] [Google Scholar]
  133. 133.
    Lȇ Cook B, Doksum T, Chen C-N, Carle A, Alegría M. 2013.. The role of provider supply and organization in reducing racial/ethnic disparities in mental health care in the U.S. . Soc. Sci. Med. 84::102–9
     [Crossref] [Google Scholar]
  134. 134.
    Lȇ Cook B, Liu Z, Lessios AS, Loder S, McGuire T. 2015.. The costs and benefits of reducing racial-ethnic disparities in mental health care. . Psychiatr. Serv. 66:(4):389–96
     [Crossref] [Google Scholar]
  135. 135.
    Lȇ Cook B, Trinh N-H, Li Z, Hou SS-Y, Progovac AM. 2017.. Trends in racial-ethnic disparities in access to mental health care, 2004–2012. . Psychiatr. Serv. 68:(1):9–16
     [Crossref] [Google Scholar]
  136. 136.
    Lee J, Gierc M, Vila-Rodriguez F, Puterman E, Faulkner G. 2021.. Efficacy of exercise combined with standard treatment for depression compared to standard treatment alone: a systematic review and meta-analysis of randomized controlled trials. . J. Affect. Disord. 295::1494–511
     [Crossref] [Google Scholar]
  137. 137.
    Leichsenring F, Steinert C, Rabung S, Ioannidis JPA. 2022.. The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses. . World Psychiatry 21:(1):133–45
     [Crossref] [Google Scholar]
  138. 138.
    Lerner D, Henke RM. 2008.. What does research tell us about depression, job performance, and work productivity?. J. Occup. Environ. Med. 50:(4):401–10
     [Crossref] [Google Scholar]
  139. 139.
    Li J-M, Zhang Y, Su W-J, Liu L-L, Gong H, et al. 2018.. Cognitive behavioral therapy for treatment-resistant depression: a systematic review and meta-analysis. . Psychiatry Res. 268::243–50
     [Crossref] [Google Scholar]
  140. 140.
    Li Y, Lv M-R, Wei Y-J, Sun L, Zhang J-X, et al. 2017.. Dietary patterns and depression risk: a meta-analysis. . Psychiatry Res. 253::373–82
     [Crossref] [Google Scholar]
  141. 141.
    Lieberman JA III. 2003.. History of the use of antidepressants in primary care. . Prim. Care Companion J. Clin. Psychiatry 5:(Suppl. 7):6–10
     [Google Scholar]
  142. 142.
    Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. 2018.. Prevalence of depression in the community from 30 countries between 1994 and 2014. . Sci. Rep. 8:(1):2861
     [Crossref] [Google Scholar]
  143. 143.
    Lin EHB, Katon W, Von Korff M, Rutter C, Simon GE, et al. 2004.. Relationship of depression and diabetes self-care, medication adherence, and preventive care. . Diabetes Care 27:(9):2154–60
     [Crossref] [Google Scholar]
  144. 144.
    Lin EHB, Rutter CM, Katon W, Heckbert SR, Ciechanowski P, et al. 2010.. Depression and advanced complications of diabetes: a prospective cohort study. . Diabetes Care 33:(2):264–69
     [Crossref] [Google Scholar]
  145. 145.
    Lipson SK, Lattie EG, Eisenberg D. 2019.. Increased rates of mental health service utilization by U.S. college students: 10-year population-level trends (2007–2017). . Psychiatr. Serv. 70:(1):60–63
     [Crossref] [Google Scholar]
  146. 146.
    Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. 2020.. Changes in the global burden of depression from 1990 to 2017: findings from the Global Burden of Disease study. . J. Psychiatr. Res. 126::134–40
     [Crossref] [Google Scholar]
  147. 147.
    López-Muñoz F, Alamo C. 2009.. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. . Curr. Pharm. Des. 15:(14):1563–86
     [Crossref] [Google Scholar]
  148. 148.
    Lopresti AL, Hood SD, Drummond PD. 2013.. A review of lifestyle factors that contribute to important pathways associated with major depression: diet, sleep and exercise. . J. Affect. Disord. 148:(1):12–27
     [Crossref] [Google Scholar]
  149. 149.
    Lotfaliany M, Bowe SJ, Kowal P, Orellana L, Berk M, Mohebbi M. 2018.. Depression and chronic diseases: co-occurrence and communality of risk factors. . J. Affect. Disord. 241::461–68
     [Crossref] [Google Scholar]
  150. 150.
    MacKenzie MB, Abbott KA, Kocovski NL. 2018.. Mindfulness-based cognitive therapy in patients with depression: current perspectives. . Neuropsychiatr. Dis. Treat. 14::1599–605
     [Crossref] [Google Scholar]
  151. 151.
    Marangell LB, Martinez M, Jurdi RA, Zboyan H. 2007.. Neurostimulation therapies in depression: a review of new modalities. . Acta Psychiatr. Scand. 116:(3):174–81
     [Crossref] [Google Scholar]
  152. 152.
    Marcantoni WS, Akoumba BS, Wassef M, Mayrand J, Lai H, et al. 2020.. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009–January 2019. . J. Affect. Disord. 277::831–41
     [Crossref] [Google Scholar]
  153. 153.
    Marcotte DE, Wilcox-Gök V, Redmon PD. 1999.. Prevalence and patterns of major depressive disorder in the United States labor force. . J. Ment. Health Policy Econ. 2:(3):123–31
     [Crossref] [Google Scholar]
  154. 154.
    Mattke S, Kapinos K, Caloyeras JP, Taylor EA, Batorsky B, et al. 2015.. Workplace wellness programs: services offered, participation, and incentives. . RAND Health Q. 5:(2):7
     [Google Scholar]
  155. 155.
    Mattke S, Liu H, Caloyeras J, Huang CY, Van Busum KR, et al. 2013.. Workplace wellness programs study. Final Rep. , RAND Corp., Santa Monica, CA:. https://www.rand.org/pubs/research_reports/RR254.html
  156. 156.
    Mattke S, Schnyer C, Van Busum KR. 2013.. A review of the U.S. workplace wellness market. . RAND Health Q. 2:(4):7
     [Google Scholar]
  157. 157.
    McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, et al. 2021.. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. . Am. J. Psychiatry 178:(5):383–99
     [Crossref] [Google Scholar]
  158. 158.
    Mekonen T, Chan GCK, Connor JP, Hides L, Leung J. 2021.. Estimating the global treatment rates for depression: a systematic review and meta-analysis. . J. Affect. Disord. 295::1234–42
     [Crossref] [Google Scholar]
  159. 159.
    Meredith LS, Cheng WJY, Hickey SC, Dwight-Johnson M. 2007.. Factors associated with primary care clinicians’ choice of a watchful waiting approach to managing depression. . Psychiatr. Serv. 58:(1):72–78
     [Crossref] [Google Scholar]
  160. 160.
    Meyerhoefer CD, Zuvekas SH. 2010.. New estimates of the demand for physical and mental health treatment. . Health Econ. 19:(3):297–315
     [Crossref] [Google Scholar]
  161. 161.
    Mezuk B, Eaton WW, Albrecht S, Golden SH. 2008.. Depression and type 2 diabetes over the lifespan: a meta-analysis. . Diabetes Care 31:(12):2383–90
     [Crossref] [Google Scholar]
  162. 162.
    Miranda J, Schoenbaum M, Sherbourne C, Duan N, Wells K. 2004.. Effects of primary care depression treatment on minority patients’ clinical status and employment. . Arch. Gen. Psychiatry 61:(8):827–34
     [Crossref] [Google Scholar]
  163. 163.
    Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, et al. 2021.. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. . Nat. Med. 27:(6):1025–33
     [Crossref] [Google Scholar]
  164. 164.
    Moitra M, Santomauro D, Collins PY, Vos T, Whiteford H, et al. 2022.. The global gap in treatment coverage for major depressive disorder in 84 countries from 2000–2019: a systematic review and Bayesian meta-regression analysis. . PLOS Med. 19:(2):e1003901
     [Crossref] [Google Scholar]
  165. 165.
    Moreno-Agostino D, Wu Y-T, Daskalopoulou C, Hasan MT, Huisman M, Prina M. 2021.. Global trends in the prevalence and incidence of depression: a systematic review and meta-analysis. . J. Affect. Disord. 281::235–43
     [Crossref] [Google Scholar]
  166. 166.
    Moshe I, Terhorst Y, Philippi P, Domhardt M, Cuijpers P, et al. 2021.. Digital interventions for the treatment of depression: a meta-analytic review. . Psychol. Bull. 147::749–86
     [Crossref] [Google Scholar]
  167. 167.
    Mossakowski KN. 2009.. The influence of past unemployment duration on symptoms of depression among young women and men in the United States. . Am. J. Public Health 99:(10):1826–32
     [Crossref] [Google Scholar]
  168. 168.
    Mrazek DA, Hornberger JC, Altar CA, Degtiar I. 2014.. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. . Psychiatr. Serv. 65:(8):977–87
     [Crossref] [Google Scholar]
  169. 169.
    Mrejen M, Hone T, Rocha R. 2022.. Socioeconomic and racial/ethnic inequalities in depression prevalence and the treatment gap in Brazil: a decomposition analysis. . SSM Popul. Health 20::101266
     [Crossref] [Google Scholar]
  170. 170.
    Naber D, Bullinger M. 2018.. Should antidepressants be used in minor depression?. Dialogues Clin. Neurosci. 20:(3):223–28
     [Crossref] [Google Scholar]
  171. 171.
    Naslund JA, Shidhaye R, Patel V. 2019.. Digital technology for building capacity of nonspecialist health workers for task-sharing and scaling up mental health care globally. . Harv. Rev. Psychiatry 27:(3):181–92
     [Crossref] [Google Scholar]
  172. 172.
    Natl. Inst. Health Care Excel. 2022.. Depression in adults: treatment and management. NICE Guidel., Manchester, UK:. https://www.nice.org.uk
  173. 173.
    NIMH (Natl. Inst. Ment. Health). 2022.. Major depression. . Mental Health Information & Statistics. https://www.nimh.nih.gov/health/statistics/major-depression
    [Google Scholar]
  174. 174.
    Nordenskjöld A, von Knorring L, Engström I. 2011.. Predictors of time to relapse/recurrence after electroconvulsive therapy in patients with major depressive disorder: a population-based cohort study. . Depress. Res. Treat. 2011::e470985
     [Google Scholar]
  175. 175.
    O'Daffer A, Colt SF, Wasil AR, Lau N. 2022.. Efficacy and conflicts of interest in randomized controlled trials evaluating Headspace and Calm apps: systematic review. . JMIR Ment. Health 9:(9):e40924
     [Crossref] [Google Scholar]
  176. 176.
    OECD. 2012.. Sick on the job? Myths and realities about mental health and work. Rep. , OECD, Paris:. https://doi.org/10.1787/22257985
  177. 177.
    Olfson M, Blanco C, Marcus SC. 2016.. Treatment of adult depression in the United States. . JAMA Intern. Med. 176:(10):1482–91
     [Crossref] [Google Scholar]
  178. 178.
    Olfson M, Marcus SC. 2009.. National patterns in antidepressant medication treatment. . Arch. Gen. Psychiatry 66:(8):848–56
     [Crossref] [Google Scholar]
  179. 179.
    Owusu JT, Wang P, Wickham RE, Cottonham DP, Varra AA, et al. 2022.. Blended care therapy for depression and anxiety: outcomes across diverse racial and ethnic groups. . J. Racial Ethn. Health Disparities. https://doi.org/10.1007/s40615-022-01450-z
    [Google Scholar]
  180. 180.
    Park LT, Zarate CA Jr. 2019.. Depression in the primary care setting. . N. Engl. J. Med. 380:(6):559–68
     [Crossref] [Google Scholar]
  181. 181.
    Patel V, Araya R, Chatterjee S, Chisholm D, Cohen A, et al. 2007.. Treatment and prevention of mental disorders in low-income and middle-income countries. . Lancet 370:(9591):991–1005
     [Crossref] [Google Scholar]
  182. 182.
    Patel V, Weobong B, Weiss HA, Anand A, Bhat B, et al. 2017.. The Healthy Activity Program (HAP), a lay counsellor-delivered brief psychological treatment for severe depression, in primary care in India: a randomised controlled trial. . Lancet 389:(10065):176–85
     [Crossref] [Google Scholar]
  183. 183.
    Patten SB, Williams JVA, Lavorato DH, Bulloch AGM, MacQueen G. 2012.. Depressive episode characteristics and subsequent recurrence risk. . J. Affect. Disord. 140:(3):277–84
     [Crossref] [Google Scholar]
  184. 184.
    Payne NA, Prudic J. 2009.. Electroconvulsive therapy: part I. A perspective on the evolution and current practice of ECT. . J. Psychiatr. Pract. 15:(5):346–68
     [Crossref] [Google Scholar]
  185. 185.
    Pearson C, Siegel J, Gold JA. 2022.. Psilocybin-assisted psychotherapy for depression: emerging research on a psychedelic compound with a rich history. . J. Neurol. Sci. 434::120096
     [Crossref] [Google Scholar]
  186. 186.
    Pelech D, Hayford T. 2019.. Medicare Advantage and commercial prices for mental health services. . Health Aff. 38:(2):262–67
     [Crossref] [Google Scholar]
  187. 187.
    Penn E, Tracy DK. 2012.. The drugs don't work? Antidepressants and the current and future pharmacological management of depression. . Ther. Adv. Psychopharmacol. 2:(5):179–88
     [Crossref] [Google Scholar]
  188. 188.
    Pereira VS, Hiroaki-Sato VA. 2018.. A brief history of antidepressant drug development: from tricyclics to beyond ketamine. . Acta Neuropsychiatr. 30:(6):307–22
     [Crossref] [Google Scholar]
  189. 189.
    Pollitz K, Rae M. 2020.. Trends in workplace wellness programs and evolving federal standards. Issue Brief, KFF, San Francisco:. https://www.kff.org/private-insurance/issue-brief/trends-in-workplace-wellness-programs-and-evolving-federal-standards/
  190. 190.
    Porter R. 2003.. Madness: A Brief History. Oxford, UK/New York:: Oxford Univ. Press
  191. 191.
    Prathikanti S, Rivera R, Cochran A, Tungol JG, Fayazmanesh N, Weinmann E. 2017.. Treating major depression with yoga: a prospective, randomized, controlled pilot trial. . PLOS ONE 12:(3):e0173869
     [Crossref] [Google Scholar]
  192. 192.
    Pratt LA, Brody DJ, Gu Q. 2017.. Antidepressant use among persons aged 12 and over: United States, 2011–2014. NCHS Data Brief 283 , Natl. Center Health Stat., Hyattsville MD:. https://www.cdc.gov/nchs/products/databriefs/db283.htm
  193. 193.
    Pridmore S. 2018.. Transcranial magnetic stimulation: an item number is justified. . Med. J. Austr. 208:(11):468
     [Crossref] [Google Scholar]
  194. 194.
    Purtle J, Nelson KL, Counts NZ, Yudell M. 2020.. Population-based approaches to mental health: history, strategies, and evidence. . Annu. Rev. Public Health 41::201–21
     [Crossref] [Google Scholar]
  195. 195.
    Qu C, Sas C, Roquet CD, Doherty G. 2020.. Functionality of top-rated mobile apps for depression: systematic search and evaluation. . JMIR Ment. Health 7:(1):e15321
     [Crossref] [Google Scholar]
  196. 196.
    Rautio N, Filatova S, Lehtiniemi H, Miettunen J. 2018.. Living environment and its relationship to depressive mood: a systematic review. . Int. J. Soc. Psychiatry 64:(1):92–103
     [Crossref] [Google Scholar]
  197. 197.
    Rea K, Wallace B. 2021.. Enhancing equity-oriented care in psychedelic medicine: utilizing the EQUIP framework. . Int. J. Drug Policy 98::103429
     [Crossref] [Google Scholar]
  198. 198.
    Read JR, Sharpe L, Modini M, Dear BF. 2017.. Multimorbidity and depression: a systematic review and meta-analysis. . J. Affect. Disord. 221::36–46
     [Crossref] [Google Scholar]
  199. 199.
    Richards D, Enrique A, Eilert N, Franklin M, Palacios J, et al. 2020.. A pragmatic randomized waitlist-controlled effectiveness and cost-effectiveness trial of digital interventions for depression and anxiety. . NPJ Digit. Med. 3:(1):85
     [Crossref] [Google Scholar]
  200. 200.
    Riemann D, Krone LB, Wulff K, Nissen C. 2020.. Sleep, insomnia, and depression. . Neuropsychopharmacology 45:(1):74–89
     [Crossref] [Google Scholar]
  201. 201.
    Rodriguez-Villa E, Naslund J, Keshavan M, Patel V, Torous J. 2020.. Making mental health more accessible in light of COVID-19: scalable digital health with digital navigators in low and middle-income countries. . Asian J. Psychiatry 54::102433
     [Crossref] [Google Scholar]
  202. 202.
    Romeo B, Karila L, Martelli C, Benyamina A. 2020.. Efficacy of psychedelic treatments on depressive symptoms: a meta-analysis. . J. Psychopharmacol. 34:(10):1079–85
     [Crossref] [Google Scholar]
  203. 203.
    Ross EL, Zivin K, Maixner DF. 2018.. Cost-effectiveness of electroconvulsive therapy versus pharmacotherapy/psychotherapy for treatment-resistant depression in the United States. . JAMA Psychiatry 75:(7):713–22
     [Crossref] [Google Scholar]
  204. 204.
    Rossom RC, Shortreed S, Coleman KJ, Beck A, Waitzfelder BE, et al. 2016.. Antidepressant adherence across diverse populations and healthcare settings. . Depress. Anxiety 33:(8):765–74
     [Crossref] [Google Scholar]
  205. 205.
    Rost K, Smith JL, Dickinson M. 2004.. The effect of improving primary care depression management on employee absenteeism and productivity. A randomized trial. . Med. Care 42:(12):1202–10
     [Crossref] [Google Scholar]
  206. 206.
    Santomauro DF, Mantilla Herrera AM, Shadid J, Zheng P, Ashbaugh C, et al. 2021.. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. . Lancet 398:(10312):1700–12
     [Crossref] [Google Scholar]
  207. 207.
    Sauvaget A, Tostivint A, Etcheverrigaray F, Pichot A, Dert C, et al. 2019.. Hospital production cost of transcranial direct current stimulation (tDCS) in the treatment of depression. . Neurophysiol. Clin. 49:(1):11–18
     [Crossref] [Google Scholar]
  208. 208.
    Sawyer MG, Reece CE, Sawyer AC, Johnson SE, Lawrence D. 2018.. Has the prevalence of child and adolescent mental disorders in Australia changed between 1998 and 2013 to 2014?. J. Am. Acad. Child Adolesc. Psychiatry 57:(5):343–350.e5
     [Crossref] [Google Scholar]
  209. 209.
    Schoenbaum M, Unützer J, Sherbourne C, Duan N, Rubenstein LV, et al. 2001.. Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial. . JAMA 286:(11):1325–30
     [Crossref] [Google Scholar]
  210. 210.
    Schueller SM, Torous J. 2020.. Scaling evidence-based treatments through digital mental health. . Am. Psychol. 75::1093–104
     [Crossref] [Google Scholar]
  211. 211.
    Scott AJ, Webb TL, Martyn-St James M, Rowse G, Weich S. 2021.. Improving sleep quality leads to better mental health: a meta-analysis of randomised controlled trials. . Sleep Med. Rev. 60::101556
     [Crossref] [Google Scholar]
  212. 212.
    Shafiei F, Salari-Moghaddam A, Larijani B, Esmaillzadeh A. 2019.. Adherence to the Mediterranean diet and risk of depression: a systematic review and updated meta-analysis of observational studies. . Nutr. Rev. 77:(4):230–39
     [Crossref] [Google Scholar]
  213. 213.
    Shorter E. 2014.. The 25th anniversary of the launch of Prozac gives pause for thought: Where did we go wrong?. Br. J. Psychiatry 204:(5):331–32
     [Crossref] [Google Scholar]
  214. 214.
    Simon GE, Ludman EJ, Rutter CM. 2009.. Incremental benefit and cost of telephone care management and telephone psychotherapy for depression in primary care. . Arch. Gen. Psychiatry 66:(10):1081–89
     [Crossref] [Google Scholar]
  215. 215.
    Singh B, Olds T, Curtis R, Dumuid D, Virgara R, et al. 2023.. Effectiveness of physical activity interventions for improving depression, anxiety and distress: an overview of systematic reviews. . Br. J. Sports Med. 57::1203–9
     [Crossref] [Google Scholar]
  216. 216.
    Singla DR. 2021.. Scaling up psychological treatments: lessons learned from global mental health. . Am. Psychol. 76::1457–67
     [Crossref] [Google Scholar]
  217. 217.
    Somani A, Kar SK. 2019.. Efficacy of repetitive transcranial magnetic stimulation in treatment-resistant depression: the evidence thus far. . Gen. Psychiatr. 32:(4):e100074
     [Crossref] [Google Scholar]
  218. 218.
    Sommers-Spijkerman M, Austin J, Bohlmeijer E, Pots W. 2021.. New evidence in the booming field of online mindfulness: an updated meta-analysis of randomized controlled trials. . JMIR Ment. Health 8:(7):e28168
     [Crossref] [Google Scholar]
  219. 219.
    Stewart MT, Horgan CM, Hodgkin D, Creedon TB, Quinn A, et al. 2018.. Behavioral health coverage under the Affordable Care Act: What can we learn from marketplace products?. Psychiatr. Serv. 69:(3):315–21
     [Crossref] [Google Scholar]
  220. 220.
    Swainson J, Reeson M, Malik U, Stefanuk I, Cummins M, Sivapalan S. 2023.. Diet and depression: a systematic review of whole dietary interventions as treatment in patients with depression. . J. Affect. Disord. 327::270–78
     [Crossref] [Google Scholar]
  221. 221.
    Thomas K, Ellis AE, Konrad TR, Holzer CE, Morrissey JP. 2009.. County-level estimates of mental health professional shortages in the Unites States. . Psychiatr. Serv. 60:(10):1323–28
     [Crossref] [Google Scholar]
  222. 222.
    Thornicroft G. 2008.. Stigma and discrimination limit access to mental health care. . Epidemiol. Psychiatr. Sci. 17:(1):14–19
     [Crossref] [Google Scholar]
  223. 223.
    Tokgöz P, Hrynyschyn R, Hafner J, Schönfeld S, Dockweiler C. 2021.. Digital health interventions in prevention, relapse, and therapy of mild and moderate depression: scoping review. . JMIR Ment. Health 8:(4):e26268
     [Crossref] [Google Scholar]
  224. 224.
    Topooco N, Riper H, Araya R, Berking M, Brunn M, et al. 2017.. Attitudes towards digital treatment for depression: a European stakeholder survey. . Internet Interv. 8::1–9
     [Crossref] [Google Scholar]
  225. 225.
    Torres NPB, Alvares-Teodoro J, Guerra Júnior AA, Barbosa MM, de Assis Acurcio F. 2022.. Social and economic factors associated with antidepressant use: results of a national survey in primary care. . J. Affect. Disord. Rep. 8::100307
     [Crossref] [Google Scholar]
  226. 226.
    Trifu S, Sevcenco A, Stănescu M, Drăgoi AM, Cristea MB. 2021.. Efficacy of electroconvulsive therapy as a potential first‑choice treatment in treatment‑resistant depression (Review). . Exp. Ther. Med. 22:(5):1281
     [Crossref] [Google Scholar]
  227. 227.
    US Bur. Labor Stat. 2021.. Consumer expenditures in 2020. BLS Rep. 1096 , Bur. Labor Stat., Washington, DC:. https://www.bls.gov/opub/reports/consumer-expenditures/2020/home.htm
  228. 228.
    van Zoonen K, Buntrock C, Ebert DD, Smit F, Reynolds CF III, et al. 2014.. Preventing the onset of major depressive disorder: a meta-analytic review of psychological interventions. . Int. J. Epidemiol. 43:(2):318–29
     [Crossref] [Google Scholar]
  229. 229.
    Vlaicu A, Bustuchina Vlaicu M. 2020.. Vagus nerve stimulation for treatment-resistant depression: Is this therapy distinct from other antidepressant treatments?. Int. J. Psychiatry Clin. Pract. 24:(4):349–56
     [Crossref] [Google Scholar]
  230. 230.
    Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, et al. 2020.. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. . Lancet 396:(10258):1204–22
     [Crossref] [Google Scholar]
  231. 231.
    Wainberg ML, Scorza P, Shultz JM, Helpman L, Mootz JJ, et al. 2017.. Challenges and opportunities in global mental health: a research-to-practice perspective. . Curr. Psychiatry Rep. 19:(5):28
     [Crossref] [Google Scholar]
  232. 232.
    Weissman CR, Bermudes RA, Voigt J, Liston C, Williams N, et al. 2023.. Repetitive transcranial magnetic stimulation for treatment-resistant depression: mismatch of evidence and insurance coverage policies in the United States. . J. Clin. Psychiatry 84:(3):22com14575
     [Crossref] [Google Scholar]
  233. 233.
    Wells KB, Sherbourne C, Schoenbaum M, Duan N, Meredith L, et al. 2000.. Impact of disseminating quality improvement programs for depression in managed primary care: a randomized controlled trial. . JAMA 283:(2):212–20
     [Crossref] [Google Scholar]
  234. 234.
    Wisniewski H, Liu G, Henson P, Vaidyam A, Hajratalli NK, et al. 2019.. Understanding the quality, effectiveness and attributes of top-rated smartphone health apps. . Evid. Based Ment. Health 22:(1):4–9
     [Crossref] [Google Scholar]
  235. 235.
    Yang F, Yang BX, Stone TE, Wang XQ, Zhou Y, et al. 2020.. Stigma towards depression in a community-based sample in China. . Compr. Psychiatry 97::152152
     [Crossref] [Google Scholar]
  236. 236.
    Zhao J-L, Jiang W-T, Wang X, Cai Z-D, Liu Z-H, Liu G-R. 2020.. Exercise, brain plasticity, and depression. . CNS Neurosci. Ther. 26:(9):885–95
     [Crossref] [Google Scholar]
/content/journals/10.1146/annurev-publhealth-061022-040533
Loading
The Economics of Treatment for Depression
Annual Review of Public Health 45, 527 (2024); https://doi.org/10.1146/annurev-publhealth-061022-040533
/content/journals/10.1146/annurev-publhealth-061022-040533
/content/journals/10.1146/annurev-publhealth-061022-040533
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error